| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/31/2001 | EP1071449A2 Antagonists of the inflammatory mediator oncostatin m (osm) |
| 01/31/2001 | EP1071448A1 Use of protease inhibitors for treating skin wounds |
| 01/31/2001 | EP1071447A1 Treatment for diabetes |
| 01/31/2001 | EP1071444A1 A method of detecting drug-receptor and protein-protein interactions |
| 01/31/2001 | EP1071434A1 Cnre binding factors and uses thereof |
| 01/31/2001 | EP1071428A2 Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 01/31/2001 | EP1071425A1 Treatment of depression and pharmaceutical preparations therefor |
| 01/31/2001 | EP1071424A1 Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph |
| 01/31/2001 | EP1071422A1 Associations de riluzole et de levodopa pour le traitement de la maladie de parkinson |
| 01/31/2001 | EP1071411A1 Topical immunostimulation to induce langerhans cell migration |
| 01/31/2001 | EP1071403A1 Pharmaceutical composition containing a statin and aspirin |
| 01/31/2001 | EP1071329A1 Methods and compositions for treatment of aids-associated kaposi's sarcoma |
| 01/31/2001 | EP0799054B1 Conjugate for treating inflammatory diseases |
| 01/31/2001 | CN1282345A Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| 01/31/2001 | CN1282254A Compositions and methods for regulating phagocytosis and ICAM-1 expression |
| 01/31/2001 | CN1282253A Small peptides and method for treatment of asthma and inflammation |
| 01/31/2001 | CN1282251A Method and material for treating and preventing mucosal tissue inflammation |
| 01/31/2001 | CN1282248A Combination effective for treatment of impotence |
| 01/31/2001 | CN1282223A Fat blend |
| 01/31/2001 | CN1282218A Compositions and method for treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 01/31/2001 | CN1061213C Method for combating fish parasites |
| 01/30/2001 | US6181962 Electrically activated substance and method for making the same |
| 01/30/2001 | US6180662 Mixture of cinnamic acid, antioxidant, enzyme, microbiocides and viricides |
| 01/30/2001 | US6180660 Cholesterol-lowering therapy |
| 01/30/2001 | US6180639 Therapy for human immunodeficiency virus |
| 01/30/2001 | US6180634 Combination therapy for the treatment of AIDS |
| 01/30/2001 | US6180624 Tachykinin antagonist and an opioid analgesic effective at treating pain or nociception |
| 01/30/2001 | US6180620 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
| 01/30/2001 | US6180616 Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function |
| 01/30/2001 | US6180604 Compositions and methods for treating infections using analogues of indolicidin |
| 01/30/2001 | US6180601 Freeze-dried soft, flexible and continous matrix of hyaluronic acid containing peptide or protein used for wound healing |
| 01/30/2001 | US6180597 Useful in treating or preventing conditions such as pulmonary hypertension, ischemic stroke, impotence, heart failure, hypoxia-induced conditions, insulin deficiency, progressive renal disease, gastric or esophageal motility syndrome, etc. |
| 01/30/2001 | US6180379 Eukaryotic transport protein; for utilization in the ubiquination and degradation of cell cycle polypeptides |
| 01/30/2001 | US6180355 Method for diagnosing and treating chronic pelvic pain syndrome |
| 01/30/2001 | US6180142 Reduction of surfactant inactivation in pulmonary surfactant therapy |
| 01/30/2001 | US6180132 Hydrogel wound dressing and the method of making and using the same |
| 01/30/2001 | US6180113 Used in tumor therapy and interventional radiology |
| 01/30/2001 | US6180095 Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| 01/30/2001 | CA2313825A1 Myostatin regulatory region, nucleotide sequence determination and methods for its use |
| 01/30/2001 | CA2272317C Pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound |
| 01/30/2001 | CA2238098C Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis |
| 01/30/2001 | CA2191352C Quinoline derivatives as tachykinin nk3 receptor antagonists |
| 01/29/2001 | CA2314682A1 A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 01/28/2001 | CA2314572A1 Estrogen agonists and antagonists for multiple indications |
| 01/25/2001 | WO2001006756A2 Use of diphenyliodonium for the activation and protection of cytotoxic lymphocytes |
| 01/25/2001 | WO2001006262A1 Diagnostics and therapeutics for macular degeneration |
| 01/25/2001 | WO2001006261A2 Screening for therapeutic agents being scap antagonists |
| 01/25/2001 | WO2001006015A1 NOVEL GLYCOSYL SULFOTRANSFERASES GST-4α, GST-4β, AND GST-6 |
| 01/25/2001 | WO2001006005A2 Diagnostic method comprising wt1 sequences |
| 01/25/2001 | WO2001005983A1 Dsp-11 dual-specificity map kinase phosphatase |
| 01/25/2001 | WO2001005972A1 Compositions and methods for the treatment of immune related diseases |
| 01/25/2001 | WO2001005970A2 Gtp-binding protein associated factors |
| 01/25/2001 | WO2001005969A2 Electron transfer proteins |
| 01/25/2001 | WO2001005968A1 Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor |
| 01/25/2001 | WO2001005954A1 Antisense modulation of liver glycogen phosphorylase expression |
| 01/25/2001 | WO2001005834A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 01/25/2001 | WO2001005833A1 Odorant receptors |
| 01/25/2001 | WO2001005831A1 Modulation of human sodium channels in dorsal root ganglia |
| 01/25/2001 | WO2001005783A1 Bradykinin b1 receptor antagonists |
| 01/25/2001 | WO2001005751A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 01/25/2001 | WO2001005749A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 01/25/2001 | WO2001005746A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 01/25/2001 | WO2001005745A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 01/25/2001 | WO2001005744A1 Novel aminobenzophenones |
| 01/25/2001 | WO2001005480A2 Chemokine binding protein of gammaherpesvirus 68 and methods of use therefor |
| 01/25/2001 | WO2001005443A1 Adhesive protein foam for surgical and/or therapeutic uses |
| 01/25/2001 | WO2001005428A1 Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof |
| 01/25/2001 | WO2001005420A1 Small peptides and methods for downregulation of ige |
| 01/25/2001 | WO2001005411A1 Compositions addressing inflammation and/or degenerative disorders |
| 01/25/2001 | WO2001005410A1 Neurotropic virus transport |
| 01/25/2001 | WO2001005405A1 Folylpolyglutamyl synthetase gene transfer to enhance antifolate drug sensitivity |
| 01/25/2001 | WO2001005388A2 Use of a fatty derivative for the treatment of external secretiondisorders |
| 01/25/2001 | WO2001005387A2 Pharmaceutical composition containing trichloroacetic acid, 2-oh benzoic and menthol for topical application, uses and process for the preparation thereof |
| 01/25/2001 | WO2001005382A1 Synergistic composition comprising daunorubicin derivatives and antimetabolite compounds |
| 01/25/2001 | WO2001005381A1 Percutaneously absorbable preparations |
| 01/25/2001 | WO2001005374A1 Methods for preparation of lipid-encapsulated therapeutic agents |
| 01/25/2001 | WO2001005373A1 Methods and apparatus for preparation of lipid vesicles |
| 01/25/2001 | WO2001005368A1 Use of at least one extract of a plant of the genus lannea in a cosmetic or dermopharmaceutical composition |
| 01/25/2001 | WO2001005362A2 Emulsifier-free finely dispersed water-in-oil-type systems |
| 01/25/2001 | WO2001005357A1 Two-component composition for cosmetic or pharmaceutical use |
| 01/25/2001 | WO2001005232A1 Stable biocidal compositions |
| 01/25/2001 | WO2001005230A1 Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof |
| 01/25/2001 | WO2000067739A3 Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
| 01/25/2001 | WO2000066550A8 New compounds |
| 01/25/2001 | WO2000066093A3 Combined preparations comprising morpholine anthracyclines and anticancer agent |
| 01/25/2001 | WO2000061171A3 Uses of mammalian ox2 protein and related reagents |
| 01/25/2001 | WO2000060080A3 Molecules of the immune system |
| 01/25/2001 | WO2000058472A3 Isolated dna encoding cullin regulators roc1 and roc2, isolated proteins encoded by the same, and methods utilizing the same |
| 01/25/2001 | WO2000057837A3 Compositions and methods for effecting the levels of cholesterol |
| 01/25/2001 | WO2000056297A3 Pharmaceutical compositions comprising dipeptidy peptidase iv inhibitors for the promotion of growth |
| 01/25/2001 | WO2000056296A3 Compositions for improving fertility |
| 01/25/2001 | WO2000048447A3 Composition for treatment of external secretion disorders except hypolacrimation |
| 01/25/2001 | CA2381327A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 01/25/2001 | CA2380000A1 Odorant receptors |
| 01/25/2001 | CA2379983A1 Dsp-11 dual-specificity map kinase phosphatase |
| 01/25/2001 | CA2379968A1 Gtp-binding protein associated factors |
| 01/25/2001 | CA2379653A1 Pharmaceutical composition for topical application, uses and process for the preparation thereof |
| 01/25/2001 | CA2379618A1 Viral protein binding compositions and methods |
| 01/25/2001 | CA2379391A1 Modulation of human sodium channels in dorsal root ganglia |
| 01/25/2001 | CA2379323A1 Small peptides and methods for downregulation of ige |